Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group
Providence Medical Group is currently enrolling patients for the following
advanced solid tumor clinical trials:
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated
Solid Tumors
Treatment: N/A
PI:
Ian Anderson, MD
Coordinator: Melissa Phillips //
Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03662204
Sponsor: Exact Sciences Corporation
A Phase II, Multicenter, Open-label study to evaluate the Efficacy and
Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of
Selected HER2-expressing Tumors (DESTINY-PanTumor02)
Treatment: Trastuzumab deruxtecan (T-DXd)
PI:
Ian Anderson, MD
Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04482309
Sponsor: AstraZeneca
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations
and c-Met Dysregulation Advanced Solid Tumors (SPARTA)
Treatment: Bozitinib (APL-101)
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability,Pharmacokinetics,
and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab
(ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic
Solid Tumors
Treatment: ABBV-927 with ABBV-368, budigalimab (ABBV-181), and/or chemotherapy
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03893955
Sponsor: AbbVie Inc.
A Multi- Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal
and Breast Cancer
Treatment: Fruquintinib
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
clinicaltrials.gov NCT No: NCT03251378
SEERPRO: A Prospective Blood Sample Collection Study To Evaluate a Panel
of Protein-based-Biomarkers
Treatment: Ibrutinib, Everolimus, Docetaxel, Paclitaxel, Cetuximab, Pembrolizumab
PI:
Manasa Vulchi, MD
Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Treatment: ladiratuzumab vedotin
PI:
Ian Anderson, MD
Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links:
clinicaltrials.gov NCT No: NCT04032704
A Study of Repotrectinib(TPX-0005) in Patients With Advanced Solid Tumors
Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
Treatment: Oral Repotrectinib
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
clinicaltrials.gov NCT No: NCT03093116
A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475)
in Patients with Selected Advanced Cancers (SELLAS)
Treatment agent: Galinpepimut-S (WT1 immunotx) + pembro
PI:
Jarrod Holmes, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
clinicaltrials.gov NCT No: NCT03761914